An early detection and treatment option would reduce healthcare cost burden on the Indian exchequer by several thousand crores in terms of disability adjusted life years (DALY)".

Biotechnology Industry: "Biotech industry expectations for dedicated research funds in the area of Biosimilars development and Regulatory Ecosystem remains unattended. India  definitely requires financial focus to ramp up this area and craft out its position in the world healthcare scene". - Medical Buyer Bureau 


 

Digital version